The Olaronke Thaddeus Foundation has expanded its fertility intervention programme, announcing free intrauterine insemination treatment for 20 Nigerian women as the cost of assisted reproduction continues to rise beyond the reach of most families. The initiative builds on a programme that has already sponsored IVF treatment for approximately 50 women and couples across Nigeria between 2024 and 2025, with support extended to Nigerians in the United Kingdom facing equivalent financial barriers.
Ugwueke-Thaddeus, who also founded Meet Surrogate Mothers, one of Nigeria’s leading assisted reproductive technology agencies, said the intervention was aimed at restoring hope to women and families for whom infertility treatment remains unaffordable.
A single IVF cycle in Nigeria currently costs between N1.7 million and N5 million, placing it entirely outside the reach of low- and middle-income earners without external support. The financial barrier is compounded by the near-total absence of public health coverage for fertility treatment in Nigeria, where assisted reproduction remains concentrated in private clinics.
The burden falls disproportionately on women, who continue to bear the social consequences of infertility stigma, marital pressure, emotional distress, and economic hardship independent of whether treatment is accessible. Private foundations operating in this space are absorbing a structural failure that public health policy has not addressed, and the scale of unmet demand is widening faster than private intervention can fill it.
The access problem is not isolated to Nigeria. In the United States, a single IVF cycle costs between $15,000 and $30,000, with most commercial insurance classifying fertility treatment as elective and therefore non-reimbursable. The Trump administration moved in 2026 to incentivise voluntary employer coverage through a proposed supplemental insurance rule with a lifetime cap of $120,000, though the rule imposes no mandate and offers no federal financial incentive to employers.
An 84% discount on select IVF medications was negotiated with drug manufacturer EMD Serono and made available via TrumpRx.gov from January 2026. In the UK, The Fertility Foundation’s IVF Grant Programme offers up to £3,000 per applicant toward private fertility treatment for eligible British citizens, with 2026 applications assessed through April.
The proliferation of grant programmes and foundation-led interventions across Nigeria, the UK, and the United States confirms a single structural reality: fertility treatment has become a two-tier system stratified entirely by income. Governments that have declined to mandate coverage or invest in public fertility infrastructure have transferred the cost of that inaction to individuals and to the charitable sector. The trajectory of IVF costs, absent structural reform, ensures that the gap between need and access will continue to widen regardless of how many foundations scale their programmes.
Also Read: The Structural Architect: How Tara Fela-Durotoye Engineered Africa’s Sovereign Beauty Ecosystem
